- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07793604
Increasing Mitochondrial Respiration as a Novel Mechanism for Cognitive Augmentation (MITOCOG)
26. August 2026 aktualisiert von: Francisco Gonzalez-Lima, PhD
The purpose of this study is to investigate the effects of increasing brain energy on cognition.
The hypothesis is that by using a special kind of light, in combination with a nutritional supplement, it may be possible to increase energy production in the brain, which may lead to improvements in cognition.
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Detaillierte Beschreibung
The Gonzalez-Lima Laboratory at the University of Texas at Austin is recruiting participants for a research study.
The study examines whether a combined treatment can improve cognitive function.
The treatment includes transcranial photobiomodulation (tPBM), a form of light therapy applied to the forehead, along with a dietary supplement.
The treatment targets an enzyme called cytochrome-c-oxidase, which plays a key role in how the mitochondria inside brain cells use oxygen to produce energy.
As people age, this process often becomes less efficient, contributing to cognitive decline seen in normal aging and in neurodegenerative diseases.
The hypothesis is that improving mitochondrial function and cytochrome-c-oxidase activity will boost neuronal energy production and reduce oxidative stress, ultimately enhancing cognitive performance.
Previous studies from the Gonzalez-Lima Lab found that applying tPBM to the prefrontal cortex improves brain metabolic activity and enhances cognitive functions such as attention, memory, and executive function.
The dietary supplement provides an alternative energy source derived from ketones, which mitochondria can use for oxygen metabolism.
This may help bypass the impaired glucose metabolism often seen in aging brains, potentially leading to further cognitive improvements.
This study will investigate the cognitive effects of this combined treatment in adults ages 18 to 85.
During the first visit to the lab, participants will complete informed consent, health questionnaires, and cognitive assessments, and wear sensors on the head which monitor brain activity.
They will also be trained to use a headset device which uses light-emitting diodes (LEDs) to deliver light to the forehead.
They will be given daily supplements and instructed on how to maintain a daily log for at-home treatments.
Then, for the next two months, participants will complete the daily protocol at home.
Weekly check-ins will monitor progress throughout this period.
After two months, participants will return to repeat the assessments from the first visit and return their study materials.
Participants will receive $200 upon completing the study, and parking expenses will be reimbursed for each visit.
Briefly, one aim will be to map the relationship between baseline prefrontal functional connectivity and dimensional performance in cognitive control and affective processing.
Another aim will be to evaluate mechanistic efficacy of chronic tPBM in engaging prefrontal circuits and restoring task-based behavioral performance.
A final aim is to model the longitudinal relationship between prefrontal circuit health and real-world sleep, circadian stability, and neuroendocrine regulation.
By focusing on target-driven biobehavioral mechanisms, this study aims to identify novel therapeutic targets and establish scalable biomarker pipelines.
Studientyp
Interventionell
Einschreibung (Geschätzt)
180
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Francisco Gonzalez-Lima
- Telefonnummer: (512) 703-1804
- E-Mail: utcognitivestudy@gmail.com
Studienorte
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78712
- The University of Texas at Austin
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria:
- Age: 18-85 years old
- No uncorrected visual, auditory, or motor impairments that would interfere with performing cognitive tasks
Exclusion Criteria:
- Transcranial photobiomodulation in the last six weeks
- Diabetes
- Pregnancy or plans to become pregnant
- Breastfeeding or plans to breastfeed
- Major depressive disorder
- Psychotic disorders
- Suicidal ideation within the past 6 months
- Plans for serious medical procedures in the next 3 months
- Serious hepatic or liver-related conditions
- History of neurotrauma (e.g., brain lesions or traumatic brain injury)
- Presently on a ketogenic diet
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Fakultätszuweisung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Arm 1: active tPBM, active MCT dietary supplementation
Participants in this arm will receive active transcranial photobiomodulation to the forehead, targeting prefrontal cortex, and active dietary supplementation with refined coconut oil to provide ketones.
|
Infrared light delivered to the forehead, administered with a headset using light-emitting diodes (LEDs)
Commercially-available food-grade refined coconut oil for ketogenic dietary supplementation
|
|
Schein-Komparator: Arm 2: sham tPBM, sham dietary supplementation
Participants in this arm will undergo the same procedures as the active group, but with sham photobiomodulation (5% of experimental light emitted by the device) and sham dietary supplementation with sunflower oil (comparable caloric value without ketone production).
|
Identical procedure as active group, but with 5% of light emitted by the device.
Identical appearance and administration as active dietary supplementation, but with commercially-available food-grade sunflower oil (comparable caloric value without ketone production).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cognitive assessment: Montreal Cognitive Assessment (MoCA)
Zeitfenster: The MoCA will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
The Montreal Cognitive Assessment is a standard questionnaire which was developed to test for cognitive impairment.
The MoCA assesses a variety of cognitive functions including executive function, memory, attention, and verbal fluency.
Minimum=0; Maximum=30; low score=more impairment.
|
The MoCA will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
|
Cognitive assessment: Trail-Making Test
Zeitfenster: The TMT will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
The trail-making test (TMT) is a paper-and-pencil "connect-the-dots" task which is used to test visual attention and cognitive flexibility.
Completion time (seconds) and number of errors are recorded.
Faster time and lower errors=better performance.
Maximum time alloted=300 seconds.
|
The TMT will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
|
Brain metabolism assessment: Functional Near-Infrared Spectroscopy (fNIRS)
Zeitfenster: The fNIRS procedure will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
Participants wear a device on the head which assesses brain metabolism non-invasively using functional near-infrared spectroscopy.
The device records changes in the concentrations of oxygenated hemoglobin in the prefrontal cortex of the brain.
|
The fNIRS procedure will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cognitive assessment: 2-Back Task
Zeitfenster: The 2-back task will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
The 2-back task is a standard computer-based test that assesses attention and short-term memory, in which participants remember a series of letters presented onscreen.
Accuracy (number of errors) and speed (reaction time in seconds) are recorded.
Faster time and lower errors=better performance.
Duration: 5 minutes.
|
The 2-back task will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
|
Cognitive assessment: Delayed Match-to-Sample Task (DMS)
Zeitfenster: The DMS will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
The DMS is a standard computer-based test that assesses visuospatial memory and attention, in which participants remember a grid pattern through a delay and then identify the correct match.
Number of correct responses and reaction time in seconds are measured.
Faster time and lower errors=better performance.
Duration=5 minutes.
|
The DMS will be administered: 1. Pre-treatment (during Visit 1); 2. Post-treatment (Visit 2, two months later)
|
|
Weekly check-in
Zeitfenster: Once per week during treatment
|
Open response, verification of compliance of treatment
|
Once per week during treatment
|
|
Follow-up
Zeitfenster: One month after Visit 2
|
Open response of any long-term effects of treatment
|
One month after Visit 2
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Oktober 2026
Primärer Abschluss (Geschätzt)
1. Dezember 2029
Studienabschluss (Geschätzt)
1. Mai 2030
Studienanmeldedaten
Zuerst eingereicht
19. August 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
26. August 2026
Zuerst gepostet (Tatsächlich)
28. August 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
28. August 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
26. August 2026
Zuletzt verifiziert
1. August 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- STUDY00009139
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Beschreibung des IPD-Plans
What data will be shared?
Individual participant data that underlie the results reported in this study, after deidentification (text, tables, figures, and appendices).
A data dictionary, including a description of the variables and types of data, collected for each individual, will be provided.
This data will include anonymized individual participant demographic information and all outcome variables (cognitive task data, spectroscopy data).
IPD-Sharing-Zeitrahmen
Beginning 9 months and ending 36 months following article publication.
IPD-Sharing-Zugriffskriterien
The raw data will be made available by the researchers upon reasonable request by any qualified doctoral researcher (PhD, MD).
They will be granted access by contacting the corresponding author/principal investigator (F.
Gonzalez-Lima, utcognitivestudy@gmail.com).
It will be made available to qualified researchers whose proposed use of the data has been approved by an independent review committee (Institutional Review Board) identified for the purpose of individual participant data meta-analysis.
Proposals may be submitted up to 36 months following article publication.
After 36 months, the data will be available in our University's shared network drive, but without investigator support other than deposited metadata.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .